vanzacaftor (VX-121) / Vertex 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
vanzacaftor (VX-121) / Vertex
NCT05867147: An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Completed
1
56
US
Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
06/23
06/23
NCT06299709: A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Completed
1
34
US
VNZ/TEZ/D-IVA, VX-121/VX-661/CTP-656, VX-121/VX-661/VX-561, Vanzacaftor/tezacaftor/deutivacaftor
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
05/24
05/24

Download Options